Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow

Executive Summary

Pfizer Inc.’s latest pledge to academic research, a five-year $85 million agreement to fund projects at the University of California, San Francisco, isn’t just a deepening of the Big Pharma’s commitment to on-campus studies intended to bridge the so-called Valley of Death between the laboratory and the commercial sector. It’s also a sign of the increased importance of deals between pharmas and universities, which give commercial partners access to new research earlier in the development process while nudging academics toward projects with commercial relevance in mind.

You may also be interested in...



Pfizer’s CTI Shows Tangible Signs Of Progress In Its Junior Year

Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.

Deals Of The Week Watches Crowdfunders Multiply Like Rabbits

VentureHealth combines the best in venture and crowdfunding, and has two exits to show for it. Plus Valeant buys Bausch & Lomb, GSK buys Okairos, AZ buys Omthera, while ThromboGenics/Array, Pfizer/UCSF, and Amgen/Astellas do deals.

Roche Teams With QB3 To Incubate Life-Science Start-Ups In Bay Area

The pharma and the incubator’s venture arm will provide seed funding for start-ups emerging from their collaborative efforts. Later, Roche may participate in Series A funding or even opt in to buy programs or whole companies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel